UROCIT-K (potassium citrate) by Mission Therapeutics is orally, the metabolism of absorbed citrate produces an alkaline load. First approved in 1985.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
UROCIT-K (potassium citrate) is an oral extended-release tablet that prevents kidney stone formation by raising urinary pH and citrate levels, making urine less conducive to crystallization of stone-forming salts. It works by metabolizing absorbed citrate to produce an alkaline load that increases urinary citrate clearance and modifies renal handling of citrate. Indicated for patients at risk of recurrent kidney stones, particularly those with low urinary citrate or hypocitraturia.
Product approaching loss of exclusivity with modest Medicare spending ($113K) and limited claims volume, indicating a mature, niche specialty market with potential for consolidation or de-emphasis.
orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase…
Worked on UROCIT-K at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on UROCIT-K offers stability in a niche specialty market with deep clinical credibility, but limited growth trajectory or innovation potential. Career development is best suited for professionals seeking to manage a mature, profitable product in a smaller therapeutic area rather than high-growth portfolio roles.